Egan-Jones Backs Pacira Management in Proxy Fight Against DOMA
Event summary
- Egan-Jones recommends Pacira shareholders vote FOR all management nominees and AGAINST DOMA's nominees in the 2026 annual meeting.
- Pacira's revenue grew 3.6% in fiscal 2025 to $726.4M, with Q1 2026 showing 5% YoY growth.
- Egan-Jones disputes DOMA's claims of EXPAREL patent risk, citing Pacira's 21-patent Orange Book estate.
- Pacira's 5x30 strategy targets $1.1B+ revenue by 2030, with 81% gross margins achieved in 2025.
- Pacira has returned $200M to shareholders under a $300M repurchase program.
The big picture
Egan-Jones' endorsement of Pacira's management reflects confidence in the company's growth trajectory and patent strategy amid activist pressure. The proxy fight highlights the tension between DOMA's push for change and Egan-Jones' view that Pacira's current leadership is best positioned to execute its 5x30 revenue strategy. The outcome will signal investor sentiment toward Pacira's ability to navigate patent risks and sustain its growth momentum in the competitive biopharmaceutical sector.
What we're watching
- Patent Defense
- Whether Pacira's expanded patent portfolio can withstand future generic challenges to EXPAREL.
- Revenue Diversification
- The pace at which Pacira can reduce reliance on EXPAREL through ZILRETTA, iovera°, and pipeline products.
- Governance Impact
- How the proxy fight outcome may influence Pacira's strategic direction and board composition.